Agendia announces companion diagnostics agreement with Daiichi Sankyo - Gilde Healthcare

Agendia announces companion diagnostics agreement with Daiichi Sankyo

25 April 2014

IRVINE, CA and AMSTERDAM – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

“This exciting early stage research collaboration represents a potential new area for additional commercialization and expansion of Agendia’s platform technology,” said David Macdonald, Agendia’s President and CEO. “We are very pleased to apply our expertise to assist with the potentially groundbreaking work being done by Daiichi Sankyo.”

Macdonald noted that Agendia has a long history of providing clinically valuable information about gene expression in oncology. “With this new agreement, our molecular diagnostics technology will now be applied to additional areas of oncology research,” he said.

As part of the agreement between Agendia and Daiichi Sankyo, Agendia technology will be used to assess patient samples. Terms and other aspects of the agreement were not disclosed.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. For more information, visit www.daiichisankyo.com.

About Agendia (www.agendia.com)

Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint, as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, and TargetPrint®, an ER/PR/HER2 expression assay. MammaPrint is the only breast cancer recurrence assay back by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

Gilde Healthcare Private Equity as part of Investor Consortium acquires DETAX

Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out and continues its successful growth track together with a strong Investor Consortium DETAX is a leading global supplier of...
3 December 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of...
1 December 2021

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor...
22 November 2021